Literature DB >> 1867955

Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.

J A Houghton1, D A Adkins, A Rahman, P J Houghton.   

Abstract

Recombinant human interferon-alpha 2a (rIFN-alpha 2a; 500 or 5,000 IU/mL) or [6RS] leucovorin ([6RS]LV; 1 microM) each potentiated the cytotoxic activity of 5-fluorouracil (FUra) by 2.6- to 3.2-fold during 72 hr exposures in two human colon adenocarcinoma cell lines (GC3/c1; VRC5/c1). When all three agents were combined, FUra cytotoxicity was further potentiated by 3.2- to 4.3-fold (total 10- to 14-fold). Potentiation of FUra cytotoxicity occurred at clinically achieveable concentrations of rIFN-alpha 2a and [6RS]LV. Effects were reversed by dThd (20 microM), although the activity of CB3717, a quinazoline-based, specific inhibitor of thymidylate synthase, was not potentiated by rIFN-alpha 2a. Data suggest the requirement of a 5-fluoropyrimidine for biochemical modulation and interaction at the level of thymidylate synthase or DNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867955     DOI: 10.3727/095535491820873236

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  8 in total

Review 1.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

2.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; S K Loftin; P J Cheshire; C L Morton; P J Houghton; A Dayan; J Jolivet
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

5.  A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer.

Authors:  M J Moore; L Kaizer; C Erlichman; R Myers; R Feld; J J Thiessen; S Fine
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

Authors:  M T Seymour; N Patel; A Johnston; S P Joel; M L Slevin
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

8.  Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.

Authors:  M T Seymour; P W Johnson; M R Hall; P F Wrigley; M L Slevin
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.